Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary arterial hypertension

Cardiovascular Journal of Africa

Volumn 21, Issue 6, 2010, Pages 334-337

  Essop, Mohammed R ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Pulmonary Hypertension Interest Group   (South Africa)

Author keywords

Mechanisms; Pulmonary hypertension; Therapy

Indexed keywords

AMBRISENTAN; BERAPROST; CALCIUM ANTAGONIST; DIGITALIS; DIHYDROPYRIDINE; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; TADALAFIL; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; WARFARIN;

ARTERY DISEASE; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE COURSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART FAILURE; HUMAN; LUNG TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; THORAX RADIOGRAPHY; VENOUS CONGESTION;

EID: 78650801120     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2010-088     Document Type: Review

References (10)

1. Romberg E. Ueber slerose lungenarterien. Deutsch Arch Klin Med 1891; 48: 197.
2. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension - A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation 2009; 119: 2250-2294.
3. Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
4. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-54.
5. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008; 118: 1486-1495.
6. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germ line mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84.
7. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744. (Pubitemid 30659603)
8. Sakoa S, Taraseviciene-Stewart L, Lee JD, et al. Initial apoptosis is followed by increased proliferation of apoptosis -resistant endothelial cells. FASEB J 2005; 19: 1178-1180.
9. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195-1201.
10. Barst RJ, Gibbs SR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-84.